These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 24407244)

  • 1. Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer.
    Zhang P; Zhang P; Shi B; Zhou M; Jiang H; Zhang H; Pan X; Gao H; Sun H; Li Z
    Cell Death Dis; 2014 Jan; 5(1):e991. PubMed ID: 24407244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Galectin-3 regulates chemotherapy sensitivity in epithelial ovarian carcinoma via regulating mitochondrial function.
    Wang D; You D; Li L
    J Toxicol Sci; 2019; 44(1):47-56. PubMed ID: 30626779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galectin-3 regulates metastatic capabilities and chemotherapy sensitivity in epithelial ovarian carcinoma via NF-κB pathway.
    Lu H; Liu Y; Wang D; Wang L; Zhou H; Xu G; Xie L; Wu M; Lin Z; Yu Y; Li G
    Tumour Biol; 2016 Aug; 37(8):11469-77. PubMed ID: 27012551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High galectin-1 expression correlates with poor prognosis and is involved in epithelial ovarian cancer proliferation and invasion.
    Kim HJ; Jeon HK; Cho YJ; Park YA; Choi JJ; Do IG; Song SY; Lee YY; Choi CH; Kim TJ; Bae DS; Lee JW; Kim BG
    Eur J Cancer; 2012 Aug; 48(12):1914-21. PubMed ID: 22386573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SNHG22 overexpression indicates poor prognosis and induces chemotherapy resistance via the miR-2467/Gal-1 signaling pathway in epithelial ovarian carcinoma.
    Zhang PF; Wu J; Luo JH; Li KS; Wang F; Huang W; Wu Y; Gao SP; Zhang XM; Zhang PN
    Aging (Albany NY); 2019 Oct; 11(19):8204-8216. PubMed ID: 31581131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-520g promotes epithelial ovarian cancer progression and chemoresistance via DAPK2 repression.
    Zhang J; Liu L; Sun Y; Xiang J; Zhou D; Wang L; Xu H; Yang X; Du N; Zhang M; Yan Q; Xi X
    Oncotarget; 2016 May; 7(18):26516-34. PubMed ID: 27049921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Helicase POLQ-like (HELQ) as a novel indicator of platinum-based chemoresistance for epithelial ovarian cancer.
    Long J; Zhu JY; Liu YB; Fu K; Tian Y; Li PY; Yang WQ; Yang SY; Yin JY; Yin G; Zhang Y
    Gynecol Oncol; 2018 May; 149(2):341-349. PubMed ID: 29572031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S100A7 Regulates Ovarian Cancer Cell Metastasis and Chemoresistance Through MAPK Signaling and Is Targeted by miR-330-5p.
    Lin M; Xia B; Qin L; Chen H; Lou G
    DNA Cell Biol; 2018 May; 37(5):491-500. PubMed ID: 29485916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells.
    Zhu X; Shen H; Yin X; Long L; Chen X; Feng F; Liu Y; Zhao P; Xu Y; Li M; Xu W; Li Y
    Oncotarget; 2017 Jun; 8(24):39154-39166. PubMed ID: 28388577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK, and cyclooxygenase-2.
    Chung LY; Tang SJ; Sun GH; Chou TY; Yeh TS; Yu SL; Sun KH
    Clin Cancer Res; 2012 Aug; 18(15):4037-47. PubMed ID: 22696230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Ovarian Epithelial Carcinoma Tumorigenesis and Progression by microRNA 106b Mediated through the RhoC Pathway.
    Chen S; Chen X; Xiu YL; Sun KX; Zhao Y
    PLoS One; 2015; 10(5):e0125714. PubMed ID: 25933027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RUNX3 contributes to carboplatin resistance in epithelial ovarian cancer cells.
    Barghout SH; Zepeda N; Vincent K; Azad AK; Xu Z; Yang C; Steed H; Postovit LM; Fu Y
    Gynecol Oncol; 2015 Sep; 138(3):647-55. PubMed ID: 26186909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of fatty acid synthase in Middle Eastern epithelial ovarian carcinoma activates AKT and Its inhibition potentiates cisplatin-induced apoptosis.
    Uddin S; Jehan Z; Ahmed M; Alyan A; Al-Dayel F; Hussain A; Bavi P; Al-Kuraya KS
    Mol Med; 2011; 17(7-8):635-45. PubMed ID: 21442130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer.
    Kritsch D; Hoffmann F; Steinbach D; Jansen L; Mary Photini S; Gajda M; Mosig AS; Sonnemann J; Peters S; Melnikova M; Thomale J; Dürst M; Runnebaum IB; Häfner N
    Int J Cancer; 2017 Oct; 141(8):1600-1614. PubMed ID: 28670762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The involvement of Bcl-2 family proteins in AKT-regulated cell survival in cisplatin resistant epithelial ovarian cancer.
    Dai Y; Jin S; Li X; Wang D
    Oncotarget; 2017 Jan; 8(1):1354-1368. PubMed ID: 27935869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HOTAIR is a potential target for the treatment of cisplatin‑resistant ovarian cancer.
    Wang Y; Wang H; Song T; Zou Y; Jiang J; Fang L; Li P
    Mol Med Rep; 2015 Aug; 12(2):2211-6. PubMed ID: 25824616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Sp1 and survivin in epithelial ovarian cancer: Sp1 inhibitor and cisplatin, a novel combination for inhibiting epithelial ovarian cancer cell proliferation.
    Sankpal UT; Ingersoll SB; Ahmad S; Holloway RW; Bhat VB; Simecka JW; Daniel L; Kariali E; Vishwanatha JK; Basha R
    Tumour Biol; 2016 Oct; 37(10):14259-14269. PubMed ID: 27581819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exon 4 deletion variant of epidermal growth factor receptor enhances invasiveness and cisplatin resistance in epithelial ovarian cancer.
    Zhang P; Zhang P; Zhou M; Jiang H; Zhang H; Shi B; Pan X; Gao H; Sun H; Li Z
    Carcinogenesis; 2013 Nov; 34(11):2639-46. PubMed ID: 23764753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
    Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
    Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.